Parsatuzumab
- CAS No.
- 1312797-14-0
- Chemical Name:
- Parsatuzumab
- Synonyms
- Parsatuzumab;Research Grade Parsatuzumab;Research Grade Parsatuzumab(DHJ76201);RG 7414|||Anti-EGFL7|||MEGF0444A|||MEGF-0444A|||RO-5490248|||M0444A
- CBNumber:
- CB68080864
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | 435M4HCP2M |
| NCI Drug Dictionary | parsatuzumab |
Parsatuzumab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0612948 | Parsatuzumab 97.40% | 1312797-14-0 | 1mg | $260 | 2026-06-04 | Buy |
| ChemScene | CS-0612948 | Parsatuzumab 97.40% | 1312797-14-0 | 5mg | $677 | 2026-06-04 | Buy |
| ChemScene | CS-0612948 | Parsatuzumab 97.40% | 1312797-14-0 | 10mg | $1083 | 2026-06-04 | Buy |
| aablocks | AA0294TG | Parsatuzumab | 1312797-14-0 | 1mg | $146 | 2026-06-02 | Buy |
| Arctom | HY-P99215 | Parsatuzumab 97.40% | 1312797-14-0 | 1mg | $228 | 2026-05-26 | Buy |
Parsatuzumab Chemical Properties, Uses, Production
Uses
Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition[1].
in vivo
Parsatuzumab (anti-EGFL7) enhances the antiangiogenesis, tumor growth control, and survival associated with antiVEGF monotherapy in several xenograft and genetically engineered murine tumor models[1].
Parsatuzumab (50 mg/kg; i.v.; 3 times per week) targets EGFL7 and inhibits mantle cell lymphoma (MCL) cell growth and prolongs survival in mouse models of MCL[2].
| Animal Model: | NSG mice injected with Rec1 cells (s.c.)[2] |
| Dosage: | 50 mg/kg |
| Administration: | Intravenous injection; 3 times per week; sacrificed mice when tumor reached end point criteria |
| Result: | Significantly decreased tumor volume than IgG and increased survival of mice. |
References
[1] García-Carbonero R, et al. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. Oncologist. 2017 Apr;22(4):375-e30. DOI:10.1634/theoncologist.2016-0133
[2] Chinmayee Goda, et al. Dorrance, Epidermal Growth Factor-like 7 As a Novel Therapeutic Target in Mantle Cell Lymphoma. Blood. 138(S1), 2021:3300.
Parsatuzumab Preparation Products And Raw materials
Raw materials
Preparation Products
Parsatuzumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| BOC Sciences | 1-631-485-4226; 16314854226 | info@bocsci.com | United States | 9920 | 65 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1577 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| Beijing Jin Ming Biotechnology Co., Ltd. | 010-60605840 | psaitong@jm-bio.com | China | 27626 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24951 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9864 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7283 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11963 | 58 |
| Wuhan Acumen Bio-Technology Co.,ltd | 027-027-16602739303 16602739303 | 673003916@qq.com | China | 4593 | 58 |
